Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.

Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.

Item

http://www.wikidata.org/entity/Q44648834

Q44648834

about

Neoadjuvant nab-paclitaxel in the treatment of breast cancer Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline Accurate data processing improves the reliability of Affymetrix gene expression profiles from FFPE samples Mechanical phenotyping of breast cancer using MEMS: a method to demarcate benign and cancerous breast tissues Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Maitake beta-glucan promotes recovery of leukocytes and myeloid cell function in peripheral blood from paclitaxel hematotoxicity Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells.Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes - what does it all mean?Neoadjuvant Therapy - What Have We Achieved in the Last 20 Years?Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial Bevacizumab added to neoadjuvant chemotherapy for breast cancer.Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.Association between HER2 status and response to neoadjuvant anthracycline followed by paclitaxel plus carboplatin chemotherapy without trastuzumab in breast cancer.Patterns of Local-Regional Management Following Neoadjuvant Chemotherapy in Breast Cancer: Results From ACOSOG Z1071 (Alliance).Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies Neoadjuvant chemotherapy and pathologic response: a retrospective cohort 99mTc-sestamibi using a direct conversion molecular breast imaging system to assess tumor response to neoadjuvant chemotherapy in women with locally advanced breast cancer Weekly taxane-anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial.H19/let-7/LIN28 reciprocal negative regulatory circuit promotes breast cancer stem cell maintenance.CMF revisited in the 21st century.Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials.Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis.Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter?Adjuvant systemic treatment for elderly breast cancer patients; addressing safety concerns.Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study.A Prospective Study on Skin-Sparing Mastectomy for Immediate Breast Reconstruction with Latissimus Dorsi Flap After Neoadjuvant Chemotherapy and Radiotherapy in Invasive Breast Carcinoma.5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial.Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism.Radiotherapy Issues After Neoadjuvant Chemotherapy.Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.Changes of oral microcirculation in chemotherapy patients: A possible correlation with mucositis?The effectiveness of simultaneous oncoplastic breast surgery in patients with locally advanced breast cancer.A phase II multicenter study of two different dosages of pemetrexed given in combination with cyclophosphamide as first-line treatment in patients with locally advanced or metastatic breast cancer.Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial.Using a novel T-lymph node ratio model to evaluate the prognosis of nonmetastatic breast cancer patients who received preoperative radiotherapy followed by mastectomy: An observational study.Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR.

P2860

Q26748822-B3405505-A276-47D1-A5D8-6A3EF671A7CD Q26853619-C1FF2A9D-2239-4F59-8665-58CAD69F26F5 Q30747169-0BA52FE6-B79D-4E5C-B287-5F8ADF079361 Q34471768-EA047247-064F-4E50-9419-438506AD8234 Q34655579-FA518EDE-6B4E-49D4-BF0D-E140EE2D3B93 Q35710628-90602712-531F-4DD5-B165-2D7D874C9C6C Q35742530-2B9CF036-6AEB-4273-B056-17624CE7D4C5 Q35782342-B940CA87-EEFF-4145-9757-983EBED414B5 Q35789457-1A9EEBDF-4D7D-41AA-87CA-E112BE92CE50 Q35889568-B12EB468-8B81-4583-863F-152AE5B52D6C Q35994850-2D4F72D5-316E-4920-BCB2-9C18E961AFE3 Q36102798-CBF5B4CA-0846-4680-A659-2C65A857F8DE Q36106083-7EB81374-A3A0-44FD-BEC3-B94E6E30F584 Q36219254-B112389D-A680-48DB-8F16-68DAF674AFF2 Q36419109-06BC562B-D5FF-4B5A-A9D1-C4C0D88D1258 Q36577603-B8549EC6-5375-4E15-A6F5-DFF51537CEE4 Q36613900-BEAF2AED-F6BF-4E73-94D3-3D31C0C40BF8 Q36935858-31073E0A-FE34-4221-88DC-B97A6F0A4BE3 Q37584757-BF37BE6E-FACA-4A31-B2F5-BEFC72299725 Q37684270-5FAF4CB4-76DE-4678-A287-50E3BC0D0EF5 Q37744868-DCF063B5-3013-41E6-985F-99608E4EE9A4 Q37895805-D2C715C2-4A6E-4E45-809C-CA7F2263ECD9 Q37903140-016603FA-1A8B-434F-8A0F-B3CA58156269 Q38017967-A76C8B69-9E3D-4FF1-BBBE-C8B9D5E5A2FA Q38195674-44D32EE1-816C-40DF-877D-DB4191F96568 Q38253136-3CEA839C-AE5D-4AAA-97D1-F0165FBA3FE5 Q38948699-B8E0A293-09E9-4E56-9F4D-74400EBBC8A6 Q39936888-C9592B7E-9F62-41F5-80FD-CC382AD148B3 Q40127291-EDA34375-EE83-4CBE-9A93-B4C676908180 Q40134207-D9F3F3AA-77D6-4BF0-B08E-DCAE87082C88 Q40847134-D7A1F9B2-AE38-4AB4-A00E-9A3999C8BA8E Q42470916-3040BD79-6AAE-44A3-B49B-0AEF72AE7BBD Q42486311-29AFFE16-A151-415B-B878-6B86AC559AA7 Q43499959-6C52D69E-F819-4CD0-94E5-2CAB0CE7E6F1 Q44256297-173CC334-0696-4E19-A375-0BC0DE6F566E Q44476507-4C20351A-9919-4A90-A725-20045DFD56EC Q45057063-79CE8190-7E38-48A1-9E94-8C47C562BFBE Q47094712-3D96CDCB-7550-43F7-BD00-51683C5991E5 Q47308042-F1242508-8B21-4973-AE5D-C954E8C37041 Q48222174-26C1CD1B-85AC-4BB9-B141-0AA55B22973B

P2860

Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.

Item

http://www.wikidata.org/entity/Q44648834

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Phase III trial evaluating the ...... ial in Operable Breast Cancer.

@en

Phase III trial evaluating the ...... ial in Operable Breast Cancer.

@nl

type

Item

label

Phase III trial evaluating the ...... ial in Operable Breast Cancer.

@en

Phase III trial evaluating the ...... ial in Operable Breast Cancer.

@nl

prefLabel

Phase III trial evaluating the ...... ial in Operable Breast Cancer.

@en

Phase III trial evaluating the ...... ial in Operable Breast Cancer.

@nl

P1476

Phase III trial evaluating the ...... rial in Operable Breast Cancer

@en

P2093

Alla Bozhok

http://www.w3.org/2001/XMLSchema#string

Angel Martinez-Agulló

http://www.w3.org/2001/XMLSchema#string

Antonio Llombart Cussac

http://www.w3.org/2001/XMLSchema#string

Dolores Sabadell

http://www.w3.org/2001/XMLSchema#string

Gianni Bonadonna

http://www.w3.org/2001/XMLSchema#string

Günther Raab

http://www.w3.org/2001/XMLSchema#string

José Baselga

http://www.w3.org/2001/XMLSchema#string

Juan Josè Lopez Lopez

http://www.w3.org/2001/XMLSchema#string

Marco Greco

http://www.w3.org/2001/XMLSchema#string

Mauro Mansutti

http://www.w3.org/2001/XMLSchema#string

P304

2474-2481

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.19.2567

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Vladimir F. Semiglazov

Luca Gianni

A Lluch

P577

2009-03-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19332727

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.

about

P2860

P2860

Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921